Skip to main content

C-RAD has signed a letter of intent regarding its GEMini technology

Press release 2009-10-28
C-RAD AB with its three fully owned subsidiaries is all active in the field of
radiation therapy. C-RAD Imaging AB and IBA Dosimetry  have signed a letter of
intent to develop and adapt the GEMini system to be integrated in the dosimetry
program sold by IBA. 

The intent is, based on an agreed upon specification and time schedule , to
develop a transparent radiation detector, based on the C-RAD GEMini technology.
For this application the C-RAD GEMini technology is offering high resolution,
low attenuation and high radiation resistance. 

The GEMini TD detector is planned to be part of the IBA solution to verify the
actual dose delivered to patients during treatment. IBA Dosimetry is the
recognized world leader in radiation therapy dosimetry and has a.o. strategic
cooperations with the Swedish company RaySearch Laboratories AB. 

The parties have the intention to sign an agreement not later than 31 December
2009. In parallel with negotiations technical performances will be evaluated by
the parties. 

Erik Hedlund, CEO, C-RAD AB:

" The IBA main requirements for a transparent  radiation detector are
challenging but can with the unique C-RAD GEMini technology be offered. The
system will be compatible with the modern treatment technologies and contribute
to an even more efficient and accurate patient treatment.” 

For further information: 

Erik Hedlund, CEO C-RAD AB, Telefon 018 - 66 69 31, E-post







Founded in 1986 in Louvain-la-Neuve, Belgium, IBA is primarily active in the
medical industry. It 

develops and markets state-of-the-art equipment and radiopharmaceuticals for
cancer diagnosis and 

treatment. In addition, it uses the scientific expertise thus gained to provide
electron accelerators for 

industrial sterilization and ionization. Listed on the pan-European stock
exchange Euronext, IBA is 

included in the BEL Mid Index (IBA: Reuters IBAB.BR and Bloomberg IBAB.BB).

Close Menu